AbbVie stock analysis
AbbVie passes 5 of 6 fundamental tests, a score of 8/10. On the daily chart it is in an uptrend, RSI 71, 2% below its 52-week high: uptrend, no fresh entry: wait for a pullback or breakout. Its own volatility puts the likely range at $265.03–$307.38 a month from now and $220.80–$368.96 in a year (68% bands).
Fundamentals 8/10
- Market cap
- $504.4 B
- P/E · forward
- 80.6 · 17.6
- PEG · P/B
- 0.6 · —
- ROE · net margin
- — · +10%
- Revenue · earnings growth
- +10% · +290%
- Debt / equity
- —
- Dividend · beta
- 2.4% · 0.2
- Next results
- 30 Oct 2026
- ✕ Net margin above 10%
- ✓ Revenue growing over 10%
- ✓ Earnings growing
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- up · 50d above 200d
- RSI(14)
- 71
- 20 / 50 / 200-day avg
- $269.93 / $262.45 / $233.95
- 20-day breakout
- above $291.40 · below $257.87
- ATR(14)
- $6.41 (2.2% a day)
- 52-week range
- $190.75 – $291.40
- Return 3m · 6m · 1y
- +13% · +37% · +24%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $265.03 – $307.38 (-7% / +8%) |
| 3 mo | $251.04 – $324.51 (-12% / +14%) |
| 6 mo | $238.04 – $342.23 (-17% / +20%) |
| 1 year | $220.80 – $368.96 (-23% / +29%) |
Analysts (28): buy, mean target $282.61 (-1%)
From its own volatility (26% a year), no drift assumed: what its swings allow, not a forecast.
AbbVie news · last two days
News lean: Neutral- 4h agoAbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?24/7 Wall St.
- 7h agoForget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate CycleMotley Fool
- 11h agoWhat AbbVie (ABBV)'s Phase 3 Lymphoma Win Means For ShareholdersSimply Wall St.
- 19h agoHere's How Many Shares of AbbVie You'd Need for $5,000 in Yearly DividendsMotley Fool
- 22h agoAbbVie or Altria: The One Dividend Stock I’d Hold for the Next 10 YearsTIKR
- 23h agoPfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?Insider Monkey
- 23h agoAbbVie vs. Merck: Which Pharma Stock Offers Better Value?Insider Monkey
- 25h agoAbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?Insider Monkey
- 41h agoAbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News LandsSimply Wall St.
- 42h agoWhat Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?Simply Wall St.
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.